在结局试验中评估接受非布司他或别嘌醇治疗的患者血清尿酸水平、痛风临床表现与心血管原因死亡的关系
基于CARES试验,痛风合并心血管疾病患者随机接受非布司他或别嘌醇治疗,中位随访32个月。在非布司他组中,血清尿酸水平、痛风发作次数或痛风石消退与心血管原因死亡无关联证据;两药在痛风合并心血管疾病患者中疗效相当。
要点
- 非布司他组血清尿酸水平在多数访视点低于别嘌醇组,但未发现与心血管原因死亡的关联。
- 非布司他组治疗1年内需治疗的痛风发作次数高于别嘌醇组(人均年暴露发作率1.33 vs 1.20),之后两药相当。
- 基线有≥1个痛风石者占20.8%,两治疗组痛风石累积消退率相似,均>50%。
核心结论
- 在CARES试验中,非布司他和别嘌醇(≤600 mg剂量)在痛风合并心血管疾病患者中疗效相当。
- 在接受非布司他的患者中,无证据表明心血管原因死亡与血清尿酸水平、痛风发作次数或痛风石消退存在关联。
研究设计与样本
- CARES试验为随机对照结局试验,患者随机接受非布司他(根据第2周血清尿酸水平给予40 mg或80 mg每日一次)或别嘌醇(按肾功能从200-400 mg或300-600 mg以100 mg递增滴定)。
- 非布司他组n=3098,别嘌醇组n=3092,中位随访32个月(最长85个月)。
- 评估指标为血清尿酸水平、痛风发作和痛风石消退相对于基线的变化,在总体人群以及心血管原因死亡与未死亡亚组中进行分析。
主要发现
- 在总体人群中,非布司他组在多数研究访视点的平均血清尿酸水平低于别嘌醇组。
- 非布司他组治疗1年内需治疗的痛风发作次数高于别嘌醇组(每人年暴露平均发作率1.33 vs 1.20),但此后两组相当。
- 整个研究期间痛风发作总体减少:治疗1年后每人年暴露平均发作率非布司他组0.35 vs 别嘌醇组0.34,总体平均发作率非布司他组0.68 vs 别嘌醇组0.63,与患者是否死于心血管原因无关。
- 基线时20.8%的患者有≥1个痛风石,两治疗组痛风石消退率相似,累积消退率>50%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) causes after treatment with febuxostat or allopurinol in patients with gout from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES) trial. METHODS: Patients were randomly assigned to receive febuxostat (40 mg or 80 mg once daily, according to serum urate levels at week 2) or allopurinol titrated in 100-mg increments from 200-400 mg or 300-600 mg (with dose determined according to kidney function). Changes from baseline in serum urate level, gout flares, and tophus resolution were key exploratory efficacy parameters in the overall population and in subgroups of patients who died and those who did not die from a CV-related cause. The latter subgroup included patients who died due to non-CV causes and those who did not die due to any cause. RESULTS: Patients received treatment with febuxostat (n = 3,098) or allopurinol (n = 3,092) for a median follow-up period of 32 months (for a maximum of 85 months). In the overall population, mean serum urate levels were lower in those receiving febuxostat compared with those receiving allopurinol at most study visits. There were no associations between serum urate levels and death from CV causes with febuxostat. The number of gout flares requiring treatment was higher within 1 year of treatment with febuxostat compared with allopurinol (mean incidence of gout flares per patient-years of exposure 1.33 versus 1.20), but was comparable thereafter and decreased overall throughout the study period (mean incidence of gout flares per patient-years of exposure 0.35 versus 0.34 after 1 year of treatment; overall mean incidence 0.68 versus 0.63) irrespective of whether the patient died from a CV-related cause. Overall, 20.8% of patients had ≥1 tophus at baseline; tophus resolution rates were similar between treatment groups, with cumulative resolution rates of >50%. CONCLUSION: In the CARES trial, febuxostat and allopurinol (≤600 mg doses) had comparable efficacy in patients with gout and CV disease, and there was no evidence of a relationship between death from CV causes and serum urate levels, number of gout flares, or tophus resolution among the patients receiving febuxostat.
引用
- Saag KG, Becker MA, White WB, et al. Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis Rheumatol. 2022. PMID: 35536764. doi:10.1002/art.42160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。